Max S. Mano

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

Medicine, Oncology, Breast Oncology +13

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 504 citations · Full text

Public Health, Health Policy, Oncology +14

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

Mônica Samuel Ávila, Silvia Moreira Ayub‐Ferreira, Mauro Rogério de Barros Wanderley et al. · Journal of the American College of Cardiology · 2018 · 497 citations

Medicine, Oncology, Pharmacology +12

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Ahmad Awada, Alain Hendlisz, Thierry Gil et al. · British Journal of Cancer · 2005 · 338 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14